Translating evidence of HDL and plaque regression
Date
2018
Authors
Di Bartolo, B.
Psaltis, P.
Bursill, C.
Nicholls, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Arteriosclerosis, Thrombosis, and Vascular Biology, 2018; 38(9):1961-1968
Statement of Responsibility
Belinda A. Di Bartolo, Peter J. Psaltis, Christina A. Bursill, Stephen J. Nicholls
Conference Name
Abstract
Considerable evidence from preclinical and population studies suggests that HDLs (high-density lipoproteins) possess atheroprotective properties. Reports from HDL infusion studies in animals and early clinical imaging trials reported evidence of plaque regression. These findings have stimulated further interest in developing new agents targeting HDL. However, the results of more recent imaging studies in the setting of high-intensity statin use have been disappointing. As the concept of plaque changes with HDL therapeutics evolves and imaging technology to evaluate these effects advances, there will become increasing opportunity to determine the effects of HDL agents on atherosclerotic plaque (Graphic Abstract).
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2018 American Heart Association, Inc.